Lack of direct comparisons prevents assessment of upadacitinib’s benefit in Crohn’s disease

  • Post author:
  • Post category:uncategorized

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency…

Continue ReadingLack of direct comparisons prevents assessment of upadacitinib’s benefit in Crohn’s disease